Cargando…
Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis
Published data regarding the overall risks and incidence of hypertension and proteinuria associated with bevacizumab were still unclear. To quantify the precise risks and incidence, we performed this comprehensive meta-analysis of 72 published clinical trials including 21902 cases and 20608 controls...
Autores principales: | Zhao, Tingting, Wang, Xiaonan, Xu, Tingting, Xu, Xiaodong, Liu, Zhihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584263/ https://www.ncbi.nlm.nih.gov/pubmed/28881662 http://dx.doi.org/10.18632/oncotarget.18190 |
Ejemplares similares
-
Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
por: Feliu, Jaime, et al.
Publicado: (2015) -
Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria
por: Saloustros, Emmanouil, et al.
Publicado: (2010) -
Effect of a Single Intravitreal Bevacizumab Injection on Proteinuria in Patients With Diabetes
por: Chung, Yoo-Ri, et al.
Publicado: (2020) -
Associations between proteinuria and cardiovascular risk factors among hypertensive patients in Andkhoy, Afghanistan
por: Shoaib Hamrah, Mohammad, et al.
Publicado: (2016) -
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)